Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Clovis, Isotopia Ink Clinical Supply Pact For Lutetium-177 Used In Its Targeted Cancer Radiation Therapy

Published 21/09/2022, 16:29
Updated 21/09/2022, 17:10
© Reuters.  Clovis, Isotopia Ink Clinical Supply Pact For Lutetium-177 Used In Its Targeted Cancer Radiation Therapy

  • Clovis Oncology Inc (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd signed a clinical supply agreement that provides Clovis Oncology with Isotopia's lutetium-177 (177Lu) n.c.a. for use in the clinical development of FAP-2286, Clovis' fibroblast activation protein (FAP)-targeting therapeutic candidate.
  • FAP-2286 is currently being investigated in the Phase 1/2 LuMIERE study for patients with advanced solid tumors.
  • The agreement covers an initial period of two years. Further details of the agreement were not disclosed.
  • 177Lu is a beta-emitting radiopharmaceutical precursor with a half-life of 6.7 days. It is used in precision oncology for targeted radionuclide therapy. It can deliver therapeutically-beneficial radiation precisely to a tumor when bound to disease-specific targeting therapeutics.
  • Isotopia's 177Lu contains no metastable 177Lum, eliminating cost-intensive clinical waste management.
  • In June, the first presentation of initial data from the Phase 1/2 LuMIERE study of FAP-2286 demonstrated a manageable safety profile and encouraging evidence of activity.
  • The company plans to present a further interim data update during the EANM Congress in October 2022.
  • Price Action: CLVS shares are up 5.36% at $1.17 on the last check Wednesday.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.